HCV Treatment
EASL 2015: Paritaprevir and Ombitasvir Are Effective for Japanese Patients with HCV Genotype 1b
- Details
- Category: HCV Treatment
- Published on Friday, 01 May 2015 00:00
- Written by Keith Alcorn
AbbVie's paritaprevir/ritonavir/ombitasvir coformulation (Viekirax in Europe; part of the Viekira Pak regimen in the U.S.) was highly effective in curing hepatitis C without the accompaniment of dasabuvir (Exviera) in Japanese people with genotype 1b hepatitis C virus (HCV) infection in the GIFT-1 trial, researchers reported at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.
EASL 2015: Another Study Confirms Detrimental Effects of Delaying Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Thursday, 30 April 2015 00:00
- Written by Liz Highleyman
Deferring antiviral therapy for hepatitis C until a person progresses to advanced liver disease has clear drawbacks including lower treatment effectiveness and an increased risk of clinical events and death, according to a study of U.S. veterans presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.
EASL 2015: Sofosbuvir-based Treatment Is Safe and Effective in Patients with Advanced Kidney Disease
- Details
- Category: HCV Treatment
- Published on Thursday, 30 April 2015 00:00
- Written by Keith Alcorn
Direct-acting antiviral therapy for hepatitis C that includes sofosbuvir (Sovaldi) can be used safely and effectively by people with very advanced kidney disease, including patients on dialysis, according to the findings of the HCV-TARGET international cohort study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.
EASL 2015: Grazoprevir/ Elbasvir Combo Cures 99% of Hepatitis C Patients with Chronic Kidney Disease
- Details
- Category: HCV Treatment
- Published on Thursday, 30 April 2015 00:00
- Written by Keith Alcorn
Merck's once-daily combination of grazoprevir and elbasvir cured hepatitis C in almost all people with advanced chronic kidney disease, researchers reported at theEuropean Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna. The findings from the C-SURFER study are the first evidence that people with chronic kidney disease stand a very high chance of being cured using an interferon-free regimen, and will offer hope to a group of people with hepatitis C until now left behind by recent advances in antiviral treatment.
EASL 2015: Patients Who Fail Short Course of Sofosbuvir/Ledipasvir Can Be Cured with 24 Weeks
- Details
- Category: HCV Treatment
- Published on Thursday, 30 April 2015 00:00
- Written by Liz Highleyman
More than 70% of genotype 1 chronic hepatitis C patients who did not achieve sustained virological response when treated with sofosbuvir/ledipasvir (Harvoni) for 8 or 12 weeks were cured with a subsequent 24-week course of the same 2 drugs, according to a study presented at the European Association for the Study of the Liver (EASL) 50th International Liver Congress last week in Vienna.
More Articles...
- EASL 2015: Grazoprevir/ Elbasvir Is Highly Effective for Previously Untreated Hepatitis C
- EASL 2015: Grazoprevir/ Elbasvir Effective for Treatment-Experienced and HIV/HCV Coinfected Patients
- EASL 2015: Sofosbuvir + Interferon/Ribavirin Effective for Hard-to-Treat Genotype 3 HCV Patients
- EASL 2015: Sofosbuvir + Daclatasvir + Ribavirin Cures Advanced Cirrhosis and Liver Transplant Patients
Web Design and Development by